Ignite Creation Date:
2024-05-06 @ 1:48 PM
Last Modification Date:
2024-10-26 @ 1:20 PM
Study NCT ID:
NCT04123795
Status:
RECRUITING
Last Update Posted:
2024-03-29
First Post:
2019-10-09
Brief Title:
A Study to Evaluate the Efficacy Safety and Drug Concentration of Certolizumab Pegol CZP in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis PSO
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
Multicenter Randomized Parallel-Group Double-Blind Placebo-Controlled 12-17 Years Including a Single Open-Label Arm 6-11 Years Study to Evaluate the Efficacy Safety and Pharmacokinetics of Certolizumab Pegol CZP in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis PSO
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CIMcare
Brief Summary:
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None